Literature DB >> 8507159

[Increased plasma levels of platelet-activating factor (PAF) and low serum PAF acetylhydrolase (PAFAH) activity in adult patients with bronchial asthma].

K Tsukioka1, M Matsuzaki, M Nakamata, H Kayahara.   

Abstract

We studied the relationship between the blood levels of platelet-activating factor (PAF) and the activity of serum PAF acetylhydrolase (PAFAH), an enzyme that inactivates PAF, in adult patients with bronchial asthma. The PAF levels in the blood and the PAFAH activity in the serum obtained from adult patients with bronchial asthma in remission (137 cases) and from healthy adult controls (106 cases) were determined by radioimmunoassay (RIA) and compared. The following results were obtained. 1. The plasma levels of PAF were significantly higher in the patients with bronchial asthma in all severity groups (mild, moderate, and severe) and all asthma types (atopic, mixed, and infectious) than in the healthy controls (p < 0.001). However, no significant differences associated with the severity and type of asthma were noted. 2. Serum PAFAH activity was significantly lower in the patients with bronchial asthma in all severity groups (mild, moderate, and severe) and asthma types (atopic, mixed, and infectious) than in the healthy controls (p < 0.001). However, no significant differences associated with the severity and type of asthma were noted. 3. PAF/PAFAH in the patients with bronchial asthma showed no significant difference associated with the severity and type of asthma. 4. There was not a significant correlation between plasma levels of PAF and serum PAFAH activity in the patients with bronchial asthma. It was, therefore, suggested that the significantly high plasma PAF levels and the significantly low serum PAFAH activity in asthmatic adults compared to the respective values in healthy controls may explain one of the mechanisms of the development and persistency of adult bronchial asthma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8507159

Source DB:  PubMed          Journal:  Arerugi        ISSN: 0021-4884


  4 in total

1.  The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma.

Authors:  S Kruse; X Q Mao; A Heinzmann; S Blattmann; M H Roberts; S Braun; P S Gao; J Forster; J Kuehr; J M Hopkin; T Shirakawa; K A Deichmann
Journal:  Am J Hum Genet       Date:  2000-03-24       Impact factor: 11.025

2.  Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma.

Authors:  D M Stafforini; T Numao; A Tsodikov; D Vaitkus; T Fukuda; N Watanabe; N Fueki; T M McIntyre; G A Zimmerman; S Makino; S M Prescott
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

3.  Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase.

Authors:  D M Stafforini; K Satoh; D L Atkinson; L W Tjoelker; C Eberhardt; H Yoshida; T Imaizumi; S Takamatsu; G A Zimmerman; T M McIntyre; P W Gray; S M Prescott
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

4.  Kupffer cell release of platelet activating factor drives dose limiting toxicities of nucleic acid nanocarriers.

Authors:  Meredith A Jackson; Shrusti S Patel; Fang Yu; Matthew A Cottam; Evan B Glass; Ella N Hoogenboezem; R Brock Fletcher; Bryan R Dollinger; Prarthana Patil; Danielle D Liu; Isom B Kelly; Sean K Bedingfield; Allyson R King; Rachel E Miles; Alyssa M Hasty; Todd D Giorgio; Craig L Duvall
Journal:  Biomaterials       Date:  2020-11-23       Impact factor: 12.479

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.